Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Novel oral anticoagulants in cardiovascular disease.

Gallego P, Roldán V, Lip GY.

J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):34-44. doi: 10.1177/1074248413501392. Epub 2013 Sep 13. Review.

PMID:
24038020
2.

Rivaroxaban: an oral factor Xa inhibitor.

Thomas TF, Ganetsky V, Spinler SA.

Clin Ther. 2013 Jan;35(1):4-27. doi: 10.1016/j.clinthera.2012.12.005. Review.

PMID:
23328267
3.

Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.

Caldeira D, Rodrigues FB, Barra M, Santos AT, de Abreu D, Gonçalves N, Pinto FJ, Ferreira JJ, Costa J.

Heart. 2015 Aug;101(15):1204-11. doi: 10.1136/heartjnl-2015-307489. Epub 2015 Jun 2. Review.

PMID:
26037103
4.

Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.

Potpara TS, Lip GY.

Prog Cardiovasc Dis. 2015 Sep-Oct;58(2):177-94. doi: 10.1016/j.pcad.2015.07.003. Epub 2015 Jul 7. Review.

PMID:
26162958
5.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
6.

Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists.

Kozlowski D, Budrejko S, Raczak G, Rysz J, Banach M.

Curr Pharm Des. 2013;19(21):3816-26. Review.

PMID:
23286429
7.

Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.

Deitelzweig S.

Cardiovasc Ther. 2014 Apr;32(2):74-81. doi: 10.1111/1755-5922.12048. Review.

PMID:
24119252
8.

Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.

Potpara TS, Dagres N, Mujović N, Vasić D, Ašanin M, Nedeljkovic M, Marin F, Fauchier L, Blomstrom-Lundqvist C, Lip GY.

Adv Ther. 2017 Feb;34(2):357-377. doi: 10.1007/s12325-016-0458-7. Epub 2016 Dec 8. Review.

9.

Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.

Becattini C, Vedovati MC, Agnelli G.

Thromb Res. 2012 Mar;129(3):392-400. doi: 10.1016/j.thromres.2011.12.014. Epub 2012 Jan 20. Review.

PMID:
22264937
10.

Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation.

Zoppellaro G, Granziera S, Padayattil Jose S, Denas G, Bracco A, Iliceto S, Pengo V.

Expert Opin Drug Saf. 2015 May;14(5):683-95. doi: 10.1517/14740338.2015.1024222. Epub 2015 Mar 24. Review.

PMID:
25803739
11.

Personalizing oral anticoagulant treatment in patients with atrial fibrillation.

Capranzano P, Miccichè E, D'Urso L, Privitera F, Tamburino C.

Expert Rev Cardiovasc Ther. 2013 Aug;11(8):959-73. doi: 10.1586/14779072.2013.818819. Epub 2013 Aug 19. Review.

PMID:
23957907
12.

Novel oral anticoagulants in non-valvular atrial fibrillation.

Potpara TS, Lip GY.

Best Pract Res Clin Haematol. 2013 Jun;26(2):115-29. doi: 10.1016/j.beha.2013.07.008. Epub 2013 Jul 21. Review.

PMID:
23953900
13.

EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.

Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P.

Eur Heart J. 2013 Jul;34(27):2094-106. doi: 10.1093/eurheartj/eht134. Epub 2013 Apr 26.

PMID:
23625209
14.
15.

Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation.

Shields AM, Lip GY.

J Intern Med. 2015 Jul;278(1):1-18. doi: 10.1111/joim.12360. Epub 2015 Apr 15. Review.

16.

Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

Cullen MW, Kim S, Piccini JP Sr, Ansell JE, Fonarow GC, Hylek EM, Singer DE, Mahaffey KW, Kowey PR, Thomas L, Go AS, Lopes RD, Chang P, Peterson ED, Gersh BJ; ORBIT-AF Investigators.

Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):461-9. doi: 10.1161/CIRCOUTCOMES.113.000127. Epub 2013 Jun 11.

17.

Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.

Galanis T, Merli GJ.

Hosp Pract (1995). 2013 Feb;41(1):26-36. doi: 10.3810/hp.2013.02.1010. Review.

PMID:
23466965
18.

Conventional and new oral anticoagulants in the treatment of chest disease and its complications.

Gallego P, Roldan V, Lip GY.

Am J Respir Crit Care Med. 2013 Aug 15;188(4):413-21. doi: 10.1164/rccm.201301-0141PP.

PMID:
23672179
19.

Transitions of care in anticoagulation management for patients with atrial fibrillation.

Deitelzweig SB.

Hosp Pract (1995). 2012 Oct;40(4):20-7. doi: 10.3810/hp.2012.10.999.

PMID:
23299032
20.

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.

Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P.

Europace. 2015 Oct;17(10):1467-507. doi: 10.1093/europace/euv309. Epub 2015 Aug 31.

PMID:
26324838

Supplemental Content

Support Center